Padeliporfin Phototherapy in Treating Patients with Recurrent Ureter and/or Renal Pelvis Urothelial Cancer

Inclusion Criteria

• Confirmed tissue diagnosis of urothelial carcinoma involving the ureter and/or renal pelvis with pathology reviewed at Memorial Sloan Kettering Cancer Center (MSKCC).
• Residual or recurrent cancer following prior endoscopic treatment.
• Ineligible, unwilling or refusing to undergo surgical management by resection of involved kidney or ureter.
• Karnofsky performance status >= 50%.
• Patients with existing ureteral obstruction and/or existing ureteral stent will be permitted. Demonstration of the site and degree of obstruction must be documented by retrograde pyelography at the time of initial and follow up endoscopic procedures within 60 days.
• Patients should not have received any systemic therapy (including chemotherapy, biologic therapy or immunotherapy) =< 4 weeks prior to treatment.
• Patients on prophylactic or full-dose anticoagulation are eligible, provided the treating physician believes it is safe to temporarily withhold anticoagulation.
• Absolute neutrophil count (ANC) >= 1,000/uL.
• Platelets >= 75,000/uL.
• Hemoglobin (Hb) >= 9 g/dl.
• International normalized ratio (INR) =< 1.5 (except for patients who are on full-dose warfarin).
• Calculated creatinine clearance >= 40 ml/min (using Cockcroft-Gault method).
• Total serum bilirubin =< 1.5 mg/dL.
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x upper limit of normal.
• Able to provide written informed consent.

Exclusion Criteria

• Pregnant or breast-feeding women. Women of childbearing potential (WOCBP) must undergo a negative pregnancy test (either serum or urine) prior to study entry. Both sexes must use contraception while on study. WOCBP include: * Any woman who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or oophorectomy) or who is not post-menopausal (defined as amenorrheic >= 12 consecutive months). * Women on hormone replacement therapy with documented serum follicle stimulating hormone level > 35 mIU/ml. * Women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as intrauterine device or barrier methods to prevent pregnancy or are practicing abstinence or where the partner is sterile.
• T4 tumors with involvement of the bowel or major blood vessels.
• Any other medical or psychiatric comorbidities, including decompensated heart failure, unstable angina or coronary artery disease or severe pulmonary disease that, in the opinion of the study investigator, would make the patient a poor candidate for the study.